vs
Side-by-side financial comparison of i-80 Gold Corp. (IAUX) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $21.3M, roughly 1.1× i-80 Gold Corp.). i-80 Gold Corp. runs the higher net margin — -401.9% vs -416.2%, a 14.3% gap on every dollar of revenue. i-80 Gold Corp. produced more free cash flow last quarter ($-39.2M vs $-69.4M).
i-80 Gold Corp is a mineral exploration and development firm focused on gold and silver asset operations in Nevada, US. It advances high-potential mining projects, using responsible extraction practices to deliver precious metals to global industrial and investment markets.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
IAUX vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $23.0M |
| Net Profit | $-85.6M | $-95.8M |
| Gross Margin | 22.0% | — |
| Operating Margin | -291.6% | -428.9% |
| Net Margin | -401.9% | -416.2% |
| Revenue YoY | — | 78.8% |
| Net Profit YoY | — | 25.7% |
| EPS (diluted) | $-0.10 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | $23.0M | ||
| Q3 25 | $32.0M | $13.8M | ||
| Q2 25 | $27.8M | $14.2M | ||
| Q1 25 | $14.0M | $16.6M | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | $11.5M | $9.1M | ||
| Q2 24 | $7.2M | $7.0M | ||
| Q1 24 | — | $28.9M |
| Q4 25 | $-85.6M | $-95.8M | ||
| Q3 25 | $-41.9M | $-101.3M | ||
| Q2 25 | $-30.2M | $-101.3M | ||
| Q1 25 | $-41.2M | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $-43.1M | $-135.7M | ||
| Q2 24 | $-41.0M | $-147.0M | ||
| Q1 24 | — | $-107.4M |
| Q4 25 | 22.0% | — | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.7% | — | ||
| Q2 24 | -171.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -291.6% | -428.9% | ||
| Q3 25 | -86.7% | -808.9% | ||
| Q2 25 | -67.4% | -772.2% | ||
| Q1 25 | -112.3% | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | -210.0% | -1589.0% | ||
| Q2 24 | -435.2% | -1998.6% | ||
| Q1 24 | — | -394.0% |
| Q4 25 | -401.9% | -416.2% | ||
| Q3 25 | -130.8% | -735.2% | ||
| Q2 25 | -108.5% | -710.8% | ||
| Q1 25 | -293.3% | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | -374.5% | -1489.5% | ||
| Q2 24 | -570.8% | -2112.6% | ||
| Q1 24 | — | -371.3% |
| Q4 25 | $-0.10 | $-0.81 | ||
| Q3 25 | $-0.05 | $-0.92 | ||
| Q2 25 | $-0.05 | $-0.98 | ||
| Q1 25 | $-0.10 | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | $-0.11 | $-1.34 | ||
| Q2 24 | $-0.11 | $-1.52 | ||
| Q1 24 | — | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.2M | $449.9M |
| Total DebtLower is stronger | $174.7M | — |
| Stockholders' EquityBook value | $346.8M | $671.4M |
| Total Assets | $703.4M | $842.1M |
| Debt / EquityLower = less leverage | 0.50× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.2M | $449.9M | ||
| Q3 25 | $102.9M | $511.0M | ||
| Q2 25 | $133.7M | $459.7M | ||
| Q1 25 | $13.5M | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | $21.8M | $658.1M | ||
| Q2 24 | $47.8M | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $174.7M | — | ||
| Q3 25 | $175.9M | — | ||
| Q2 25 | $175.8M | — | ||
| Q1 25 | $197.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $346.8M | $671.4M | ||
| Q3 25 | $423.0M | $748.4M | ||
| Q2 25 | $463.5M | $715.3M | ||
| Q1 25 | $318.0M | $779.9M | ||
| Q4 24 | — | $872.0M | ||
| Q3 24 | $346.9M | $962.6M | ||
| Q2 24 | $377.2M | $971.1M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | $703.4M | $842.1M | ||
| Q3 25 | $756.2M | $925.3M | ||
| Q2 25 | $782.9M | $898.9M | ||
| Q1 25 | $659.0M | $986.2M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $-69.3M |
| Free Cash FlowOCF − Capex | $-39.2M | $-69.4M |
| FCF MarginFCF / Revenue | -184.3% | -301.6% |
| Capex IntensityCapex / Revenue | 23.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.2M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | $-69.3M | ||
| Q3 25 | $-15.2M | $-76.9M | ||
| Q2 25 | $-11.3M | $-99.6M | ||
| Q1 25 | $-22.7M | $-148.9M | ||
| Q4 24 | — | $-85.2M | ||
| Q3 24 | $-23.5M | $-84.8M | ||
| Q2 24 | $-24.6M | $-58.2M | ||
| Q1 24 | — | $-120.7M |
| Q4 25 | $-39.2M | $-69.4M | ||
| Q3 25 | $-18.5M | $-76.9M | ||
| Q2 25 | $-12.4M | $-99.9M | ||
| Q1 25 | $-23.1M | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | $-23.8M | $-86.1M | ||
| Q2 24 | $-25.1M | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | -184.3% | -301.6% | ||
| Q3 25 | -57.8% | -558.2% | ||
| Q2 25 | -44.7% | -701.0% | ||
| Q1 25 | -164.1% | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | -206.7% | -945.2% | ||
| Q2 24 | -349.1% | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | 23.1% | 0.5% | ||
| Q3 25 | 10.2% | 0.2% | ||
| Q2 25 | 3.9% | 1.7% | ||
| Q1 25 | 2.5% | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | 2.5% | 14.0% | ||
| Q2 24 | 7.3% | 14.5% | ||
| Q1 24 | — | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IAUX
| Granite Creek Mining Company | $20.3M | 95% |
| Ruby Hill Mining Company LLC | $991.0K | 5% |
| Lone Tree Minning Company | $3.0K | 0% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
